

# Jennifer A Woyach

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4025508/jennifer-a-woyach-publications-by-year.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

104 papers	5,439 citations	28 h-index	73 g-index
109 ext. papers	6,700 ext. citations	7 avg, IF	5.37 L-index

#	Paper	IF	Citations
104	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.. <i>Leukemia</i> , <b>2022</b> ,	10.7	15
103	A CAPTIVATE-ing new regimen for CLL. <i>Blood</i> , <b>2022</b> , 139, 3229-3230	2.2	1
102	Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition.. <i>Cancer Research Communications</i> , <b>2021</b> , 1, 79-89		1
101	Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia. <i>Nature Communications</i> , <b>2021</b> , 12, 6338	17.4	0
100	Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation. <i>Blood</i> , <b>2021</b> , 138, 2252-2252	2.2	
99	Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients. <i>Cell and Bioscience</i> , <b>2021</b> , 11, 197	9.8	10
98	Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study. <i>Blood</i> , <b>2021</b> , 138, 392-392	2.2	2
97	Characterization of LP-118, a Novel Small Molecule Inhibitor of Bcl-2 and Bcl-XL in Chronic Lymphocytic Leukemia Resistant to Venetoclax. <i>Blood</i> , <b>2021</b> , 138, 679-679	2.2	0
96	Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial. <i>Blood</i> , <b>2021</b> , 138, 2642-2642	2.2	1
95	Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. <i>Leukemia</i> , <b>2021</b> , 35, 3287-3290	10.7	
94	Acalabrutinib in treatment-naive chronic lymphocytic leukemia. <i>Blood</i> , <b>2021</b> , 137, 3327-3338	2.2	18
93	A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, 766-774	2	2
92	Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 716-721	1.9	0
91	Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 17	22.4	4
90	Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 36	22.4	3
89	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. <i>Leukemia</i> , <b>2021</b> , 35, 2854-2861	10.7	2
88	Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 3278-3282	1.9	1

87	Genomics of Resistance to Targeted Therapies. <i>Hematology/Oncology Clinics of North America</i> , <b>2021</b> , 35, 715-724	3.1	
86	Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Cancer Discovery</i> , <b>2020</b> , 10, 394-405	24.4	38
85	Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , <b>2020</b> , 136, 22-23	2.2	1
84	Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy. <i>Blood</i> , <b>2020</b> , 136, 29-30	2.2	
83	Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib. <i>Blood</i> , <b>2020</b> , 136, 32-33	2.2	3
82	Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Blood</i> , <b>2020</b> , 136, 2-3	2.2	1
81	Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2020</b> , 136, 9-10	2.2	9
80	Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts. <i>NAR Genomics and Bioinformatics</i> , <b>2020</b> , 2, lqaa070	3.7	0
79	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3626-3637	7.2	34
78	Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6187-6195	12.9	3
77	Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry. <i>Nature Communications</i> , <b>2020</b> , 11, 4268	17.4	45
76	Targeting phosphatidylinositol 3 kinase- $\delta$ and - $\epsilon$ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma. <i>Blood Advances</i> , <b>2020</b> , 4, 4382-4392	7.8	9
75	T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 7-15	4.7	22
74	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. <i>Lancet, The</i> , <b>2020</b> , 395, 1278-1291	40	201
73	BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL. <i>Therapeutic Advances in Hematology</i> , <b>2020</b> , 11, 2040620720912990	5.7	5
72	Current Perspectives on Therapy for Chronic Lymphocytic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2020</b> , 40, 1-10	7.1	10
71	Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. <i>Leukemia</i> , <b>2019</b> , 33, 2527-2530	10.7	51
70	Representation of Patients With Cardiovascular Disease in Pivotal Cancer Clinical Trials. <i>Circulation</i> , <b>2019</b> , 139, 2594-2596	16.7	16

69	Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 363-366	4.5	12
68	Contemporary impacts of a cancer diagnosis on survival following in-hospital cardiac arrest. <i>Resuscitation</i> , <b>2019</b> , 142, 30-37	4	8
67	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 1353-1363	7.1	152
66	Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib. <i>British Journal of Haematology</i> , <b>2019</b> , 187, 399-402	4.5	6
65	EBTCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6260-6273	12.9	11
64	Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy. <i>Blood</i> , <b>2019</b> , 134, 3045-3045	2.2	1
63	A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2019</b> , 134, 3049-3049	2.2	2
62	Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial). <i>Blood</i> , <b>2019</b> , 134, 1754-1754	2.2	7
61	Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2019</b> , 134, 2526-2526	2.2	0
60	LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia. <i>Blood</i> , <b>2019</b> , 134, 3377-3377	2.2	2
59	The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2019</b> , 134, 2077-2077	2.2	0
58	HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 2308-2311	1.9	4
57	Treatment-naïve CLL: lessons from phase 2 and phase 3 clinical trials. <i>Hematology American Society of Hematology Education Program</i> , <b>2019</b> , 2019, 476-481	3.1	2
56	Hypertension and incident cardiovascular events following ibrutinib initiation. <i>Blood</i> , <b>2019</b> , 134, 1919-1928	2.2	79
55	BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. <i>Cancer Discovery</i> , <b>2018</b> , 8, 458-477	24.4	67
54	Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 1461-1465	1.9	1
53	The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. <i>Cancer Discovery</i> , <b>2018</b> , 8, 1300-1315	24.4	73
52	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 2517-2528	59.2	455

51	How I manage ibrutinib-refractory chronic lymphocytic leukemia. <i>Blood</i> , <b>2017</b> , 129, 1270-1274	2.2	35
50	The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2831-2841	12.9	88
49	The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia. <i>Cancer Medicine</i> , <b>2017</b> , 6, 778-787	4.8	12
48	Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. <i>Blood Advances</i> , <b>2017</b> , 1, 1739-1748	7.8	85
47	Ibrutinib treatment improves T cell number and function in CLL patients. <i>Journal of Clinical Investigation</i> , <b>2017</b> , 127, 3052-3064	15.9	197
46	Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center. <i>Blood</i> , <b>2017</b> , 130, 830-830	2.2	25
45	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 323-32	59.2	621
44	Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders. <i>Clinics in Geriatric Medicine</i> , <b>2016</b> , 32, 175-89	3.8	6
43	Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia. <i>Blood</i> , <b>2016</b> , 128, 1259-1259	2.2	3
42	Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center. <i>Blood</i> , <b>2016</b> , 128, 2040-2040	2.2	1
41	Role of Histone Deacetylase-Mediated Gene Silencing in Chronic Lymphocytic Leukemia Progression. <i>Blood</i> , <b>2016</b> , 128, 2705-2705	2.2	1
40	The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2016</b> , 128, 3232-3232	2.2	14
39	Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism. <i>Blood</i> , <b>2016</b> , 128, 3238-3238	2.2	5
38	Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL. <i>Blood</i> , <b>2016</b> , 128, 4385-4385	2.2	1
37	Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones. <i>Blood</i> , <b>2016</b> , 128, 4386-4386	2.2	2
36	Major Bleeding Complications Among Patients Treated with Ibrutinib and Concomitant Antiplatelet, Anticoagulant, or Supplemental Therapy. <i>Blood</i> , <b>2016</b> , 128, 4387-4387	2.2	7
35	A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features. <i>Blood</i> , <b>2016</b> , 128, 4388-4388	2.2	2
34	REDX08608, a Novel, Potent and Selective, Reversible BTK Inhibitor with Efficacy and Equivalent Potency Against Wild-Type and Mutant C481S BTK. <i>Blood</i> , <b>2016</b> , 128, 4399-4399	2.2	4

33	the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL. <i>Blood</i> , <b>2016</b> , 128, 55-55	2.2	7
32	Phase 1b Results of a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , <b>2016</b> , 128, 639-639	2.2	21
31	Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. <i>Blood</i> , <b>2016</b> , 128, 3198-3198	2.2	
30	Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo. <i>Blood</i> , <b>2016</b> , 128, 352-352	2.2	1
29	Targeting BTK through microRNA in chronic lymphocytic leukemia. <i>Blood</i> , <b>2016</b> , 128, 3101-3112	2.2	25
28	Secondary autoimmune cytopenias in chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , <b>2016</b> , 43, 300-310	2.2	16
27	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. <i>Blood</i> , <b>2016</b> , 127, 1117-27	2.2	282
26	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , <b>2015</b> , 1, 80-7	13.4	398
25	Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3705-15	12.9	147
24	Patterns of resistance to B cell-receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management. <i>Hematology American Society of Hematology Education Program</i> , <b>2015</b> , 2015, 355-60	3.1	17
23	OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. <i>Blood</i> , <b>2015</b> , 125, 284-95	2.2	15
22	Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. <i>Blood</i> , <b>2015</b> , 126, 842-50	2.2	111
21	Targeted therapies in CLL: mechanisms of resistance and strategies for management. <i>Blood</i> , <b>2015</b> , 126, 471-7	2.2	96
20	Jumping translocations, a novel finding in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , <b>2015</b> , 170, 200-7	4.5	7
19	Targeting BTK By a microRNA Mechanism in Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2015</b> , 126, 1232-1232	2.2	1
18	The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2015</b> , 126, 2920-2920	2.2	7
17	Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , <b>2015</b> , 126, 2940-2940	2.2	3
16	A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , <b>2015</b> , 126, 2953-2953	2.2	2

15	A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and In Vitro Potency in B-Cell Malignancies. <i>Blood</i> , <b>2015</b> , 126, 318-318	2.2	
14	Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies. <i>Blood</i> , <b>2015</b> , 126, 317-317	2.2	0
13	The E $\mu$ -Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing. <i>Blood</i> , <b>2015</b> , 126, 2752-2752	2.2	3
12	Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 2286-94	59.2	800
11	A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. <i>Blood</i> , <b>2014</b> , 124, 3553-60	2.2	44
10	Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). <i>Blood</i> , <b>2014</b> , 123, 1207-13	2.2	144
9	Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. <i>Blood</i> , <b>2014</b> , 123, 1810-7	2.2	218
8	Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype. <i>Blood</i> , <b>2013</b> , 122, 2872-2872	2.2	
7	OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , <b>2013</b> , 122, 2523-2523	2.2	
6	The B-cell receptor signaling pathway as a therapeutic target in CLL. <i>Blood</i> , <b>2012</b> , 120, 1175-84	2.2	291
5	Translating PI3K-Delta Inhibitors to the Clinic in Chronic Lymphocytic Leukemia: The Story of CAL-101 (GS1101). <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2012</b> , 691-4	7.1	7
4	Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1349-55	2.2	113
3	Response, Progression-Free Survival, and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities. <i>Blood</i> , <b>2010</b> , 116, 2456-2456	2.2	1
2	New therapeutic advances in the management of progressive thyroid cancer. <i>Endocrine-Related Cancer</i> , <b>2009</b> , 16, 715-31	5.7	39
1	Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 164-70	5.6	120